Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance
Authors:
- Maicol ManciniMMMaicol Mancini
- Quentin-Dominique ThomasQTQuentin-Dominique Thomas
- Sylvia BourdelSBSylvia Bourdel
- Laura PaponLPLaura Papon
- Emilie BousquetEBEmilie Bousquet
- Prisca JaltaPJPrisca Jalta
- Silvia La MonicaSilvia La Monica
- Camille TravertCTCamille Travert
- Roberta AlfieriRoberta Alfieri
- Xavier QuantinXQXavier Quantin
- Marta CañameroMCMarta Cañamero
- Antonio MaraverAntonio Maraver
Open Access
Abstract
Despite the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) to treat advanced lung cancer harboring EGFR-activating mutations, the prognosis remains unfavorable because of intrinsic and/or acquired resistance. We generated a new state-of-the-art mouse strain harboring the human EGFRT790M/L858R oncogene and MET overexpression (EGFR/MET strain) that mimics the MET amplification occurring in one out of five patients with EGFR-mutated lung cancer that relapsed after treatment with osimertinib, a third-generation anti-EGFR TKI. We found that survival was reduced in EGFR/MET mice compared with mice harboring only EGFRT790M/L858R (EGFR strain). Moreover, EGFR/MET-driven lung tumors were resistant to osimertinib, recapitulating the phenotype observed in patients. Conversely, as also observed in patients, the crizotinib (anti-MET TKI) and osimertinib combination improved survival and reduced tumor burden in EGFR/MET mice, further validating the model’s value for preclinical studies. We also found that in EGFR/MET mice, MET overexpression negatively regulated EGFR activity through MIG6 induction, a compensatory mechanism that allows the coexistence of the two onco-genic events. Our data suggest that single EGFR or MET inhibition might not be a good therapeutic option for EGFR-mutated lung cancer with MET amplification, and that inhibition of both pathways should be the best clinical choice in these patients.Keywords
Funding Information
- National Cancer Institute (INCa_9257)
- Institut National Du Cancer (12553)
This publication has 21 references indexed in Scilit:
- Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A ReviewJournal of Clinical Oncology, 2020
- Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyThe Lancet Oncology, 2020
- Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinomaJournal of Clinical Investigation, 2019
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of CancerCell, 2018
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung CancerNew England Journal of Medicine, 2017
- Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeuticsSeminars in Cell & Developmental Biology, 2016
- Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancerThe Lancet Oncology, 2015
- The Metabolic Profile of Tumors Depends on Both the Responsible Genetic Lesion and Tissue TypeCell Metabolism, 2012
- Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/Met-induced cell migration and neurite growthJournal of Cell Biology, 2005